Mannkind (MNKD) Amortizatization of Intangibles (2019 - 2026)
Mannkind (MNKD) reported Amortizatization of Intangibles of $532000.0 for Q1 2026, down 2.21% year-over-year from $544000.0 in Q1 2025, and up 188.23% on a QoQ basis from -$603000.0 in Q4 2025.
Mannkind (MNKD) has 8 years of Amortizatization of Intangibles data on file, last reported at $532000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 2.21% year-over-year to $532000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 36.31% YoY) and the FY2025 annual result came in at $1.2 million, down 27.34% from the prior year.
- Amortizatization of Intangibles climbed to $532000.0 in Q1 2026 per MNKD's latest filing, from -$603000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.0 million in Q2 2022 and bottomed at -$603000.0 in Q4 2025.
- The 5-year median for Amortizatization of Intangibles is $332000.0 (2022), against an average of $452941.2.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles soared 468.8%; it then tumbled 214.2% in 2025.
- Tracing MNKD's Amortizatization of Intangibles over 5 years: stood at $332000.0 in 2022, then retreated by 2.71% to $323000.0 in 2023, then soared by 63.47% to $528000.0 in 2024, then plunged by 214.2% to -$603000.0 in 2025, then surged by 188.23% to $532000.0 in 2026.
- Per Business Quant, the three latest MNKD Amortizatization of Intangibles figures stand at $532000.0 (Q1 2026), -$603000.0 (Q4 2025), and $740000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 532,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | -603,000.00 |
| Dec 31, 2025 | -603,000.00 |
| Sep 30, 2025 | 740,000.00 |
| Sep 30, 2025 | 740,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Dec 31, 2023 | 323,000.00 |
| Dec 31, 2023 | 323,000.00 |
| Sep 30, 2023 | 321,000.00 |
| Sep 30, 2023 | 321,000.00 |
| Jun 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 319,000.00 |
| Mar 31, 2023 | 338,000.00 |
| Mar 31, 2023 | 338,000.00 |
| Dec 31, 2022 | 332,000.00 |
| Dec 31, 2022 | 332,000.00 |
| Sep 30, 2022 | 324,000.00 |
| Sep 30, 2022 | 324,000.00 |
| Jun 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.04 Mn |
| Mar 31, 2022 | 289,000.00 |
| Mar 31, 2022 | 289,000.00 |
| Dec 31, 2021 | 753,000.00 |
| Dec 31, 2021 | 753,000.00 |
| Sep 30, 2021 | -163,000.00 |
| Sep 30, 2021 | -163,000.00 |
| Jun 30, 2021 | 359,000.00 |
| Jun 30, 2021 | 359,000.00 |
| Mar 31, 2021 | 309,000.00 |
| Mar 31, 2021 | 309,000.00 |
| Dec 31, 2020 | 298,000.00 |
| Dec 31, 2020 | 298,000.00 |
| Sep 30, 2020 | 303,000.00 |
| Sep 30, 2020 | 303,000.00 |
| Jun 30, 2020 | 294,000.00 |
| Jun 30, 2020 | 294,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Dec 31, 2019 | 279,000.00 |
| Dec 31, 2019 | 279,000.00 |
| Sep 30, 2019 | 285,000.00 |
| Sep 30, 2019 | 285,000.00 |
| Jun 30, 2019 | 223,000.00 |
| Jun 30, 2019 | 223,000.00 |
| Mar 31, 2019 | 395,000.00 |
| Mar 31, 2019 | 395,000.00 |